Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and has higher risk of recurrence than HER2-negative cancer. With few treatment options available, new drug targets specific for HER2-positive breast cancer are needed.

Methods

We conducted a pharmacological profiling of seven genotypically distinct breast cancer cell lines using a subset of inhibitors of breast cancer cells from a screen of the Johns Hopkins Drug Library. To identify molecular targets of nelfinavir, identified in the screen as a selective inhibitor of HER2-positive cells, we conducted a genome-wide screen of a haploinsufficiency yeast mutant collection. We evaluated antitumor activity of nelfinavir with xenografts in athymic nude mouse models (n = 4-6 per

SUBMITTER: Shim JS 

PROVIDER: S-EPMC3472971 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature